In this volume, an international team of experts in chronic myeloid leukemia share their expertise. In particular, they contribute their insights on the latest advances in understanding this disease, and the implications those developments have for its management. They explore many topics, including a review of molecular and cellular biology, discussion of conventional chemotherapy and interferon therapy, and recent developments in allografting and autografting. The reader gains not only an incisive view of the biological structure of the disease, but applications of that biology to treatment modalities. Chronic Myeloid Leukemia is ideal for oncologists and other specialists in the field.
Indice testuale
Part 1. Molecular Biology: BCR/ABL Gene Structure and BCR Function. BCR/ABL Protein Domain Function and Signaling. Adhesion/Integrin Abnormalities. Animal Models. Progenitor Cell Dynamics. Target-Directed Therapies. Complementation of Cytokine Signaling Pathways. Part 2. Conventional Therapy: IFN Dosage Regimens. Chemotherapy vs IFN. Biology of IFN. Prognostic Scores in CML. Chemotherapy and Combination Chemotherapy. IFN and Ara-C. Part 3. Allografting: Donor Selection. Prognostic Factors. Timing. Conditioning Regimens. Blood vs Marrow Stem Cells. Results with Sibling/Alternative Donors. Monitoring. Relapse. Basis of GVL. Donor Lymphocyte Infusions. Part 4. Autografting: Genetic Approaches to Treatment of CML. Specific Chemical Inhibitors of ABL Tyrosine Kinase. Immunotherapeutic Strategies. Autografting with Unmanipulated Stem Cells. Autografting with Cultured Marrow. Autografting with Ph-Negative Hematopoietic Progenitor Cells. Long-term Follow-up of Autologous Transplant Therapy. Target-Directed Therapies and ST1571.
